Skip to content

Talphera, Inc. TLPH Return on equity

Return on equity at other companies

Baxter International logo
Baxter InternationalBAX
-16.7%-76.7pp
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-189.5%-8,509pp
Royalty Pharma logo
Royalty PharmaRPRX
8.4%-2.7pp
XOMA Corporation logo
XOMA CorporationXOMA
38.1%+35.2pp
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
174.1%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
100.7%+60.3pp

Other financials

Income statement

See full
Revenue--100%
Gross profit-$1.9M-52.7%
Operating income-$3.9M-35.4%
Net income-$2.6M+1.4%
EPS (diluted)-$0.10+37.5%

Balance sheet

See full
Cash & equivalents$3.8M-29.0%
Total debt$3.4M-79.7%
Total equity$18.5M+230%
Total assets$30.2M+101%

Cash flow

See full
Operating cash flow-$3.4M+2.0%
CapEx-
Free cash flow-$2.3M+42.9%

Valuation

See full
Market cap$53.46M+493%
P/S53,456.6×+53,123×

Profitability

See full
Gross margin-127.7%-136pp
Operating margin-1,451,600%-1,507,145pp
Net margin-1,425,300%-1,471,200pp
FCF margin-5,116.7%-6,779pp

Returns & leverage

See full
Debt / equity0.2×
Current ratio5.3×+2.2×

Where this comes from

Calculated from Talphera, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Talphera, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Talphera, Inc.'s return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Talphera, Inc.'s return on equity?
Talphera, Inc. (TLPH) reported return on equity of -118.4% in Q1 2026.
How has Talphera, Inc.'s return on equity changed year-over-year?
Talphera, Inc.'s return on equity decreased by 11.5% year-over-year, from -106.2% to -118.4%.
What is the long-term trend for Talphera, Inc.'s return on equity?
Over 2 years (2023 to 2025), Talphera, Inc.'s return on equity has grown at a 5.6% compound annual growth rate (CAGR), from -102.4% to -114.2%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.